Questions
Thymosin Alpha-1: Your Questions, Answered Straight
Direct answers, cited to the studies, with the honest caveats left in.
Is thymosin alpha 1 FDA-approved?
No. Thymosin Alpha-1 (thymalfasin) is not approved for marketing in the United States. It is approved in roughly 35 other countries for indications such as chronic hepatitis B and immune support [4]. In the US it exists only in investigational and compounding/research contexts, and US regulators have reviewed but not endorsed it for compounding [16].
Who should not take thymosin alpha 1?
The literature flags theoretical cautions rather than firm contraindications: people with autoimmune disease [14] or a solid-organ transplant [5], because the peptide stimulates immunity, and anyone pregnant or breastfeeding, since dedicated safety data are absent [4]. These are mechanism-based cautions, not tested outcomes. This is not medical advice; medical decisions belong with a qualified clinician.
Is thymosin alpha 1 worth it?
It depends entirely on the setting. The strongest evidence is in chronic hepatitis B, where adding it to antiviral therapy improved viral control [9]. Outside that, results are mixed-to-null — most notably the phase-3 TESTS sepsis trial found no survival benefit (HR 0.99, P=0.93) [3]. The evidence supports cautious optimism in specific indications, not a blanket endorsement.
Is thymosin alpha 1 legit or a scam peptide?
The molecule itself is legitimate and well studied — a 28-amino-acid thymic peptide with four decades of trials and an approved drug form abroad [4]. The scam risk is the supply chain: because it is not US-approved, unregulated research-grade vials may be underdosed, mislabeled, or not the peptide claimed, with no consumer-facing quality oversight [4]. The science is real; the sourcing is where caution belongs.
Is thymosin alpha 1 a steroid?
No. Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated peptide isolated from calf thymus, with its full sequence determined by Goldstein and colleagues in 1977 [1]. Steroids are lipid-based hormones with a four-ring structure; this is a peptide (a short protein) and an immune modulator, not a steroid and not an anabolic agent.
What is thymalfasin?
Thymalfasin is the International Nonproprietary Name (INN) for the synthetic, sequence-identical form of Thymosin Alpha-1 used in clinical trials and approved abroad [4]. In other words, thymalfasin and Thymosin Alpha-1 are the same 28-amino-acid molecule — one name is the natural peptide, the other is its manufactured drug equivalent.
Is thymosin alpha 1 banned by WADA?
Thymosin Alpha-1 is not specifically named as a prohibited substance on the WADA Prohibited List, but immunomodulatory peptides sit in a regulatory grey area and athletes should verify against the current List before relying on this. Note that the often-confused peptide thymosin beta-4 (TB-500) is explicitly WADA-prohibited — they are different molecules.
Is thymosin alpha 1 effective for sepsis?
The best evidence says no clear benefit. The multicentre ETASS trial of 361 patients suggested a mortality reduction (26.0% vs 35.0%) that fell just short of significance [2], but the definitive phase-3 TESTS trial of 1,106 adults found no significant 28-day mortality difference (23.4% vs 24.1%; HR 0.99, P=0.93) [3]. The largest, most rigorous trial was null.
Is thymosin alpha 1 legal in the US?
It is not FDA-approved for marketing in the US, so it cannot be sold as an approved drug; US availability is limited to investigational and compounding contexts, and regulators have reviewed but not endorsed it for compounding [16]. Legal status for research material is distinct from drug approval and varies by context — this site does not give legal advice.
What is thymosin alpha 1?
Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated thymic peptide, cleaved in the body from the precursor prothymosin alpha and first isolated and sequenced from calf thymus by Goldstein and colleagues in 1977 [1]. It is an immunomodulator that helps immune cells mature and coordinate, and its synthetic drug form is called thymalfasin.
What does thymosin alpha 1 do?
It adjusts immune function. Thymosin Alpha-1 signals through Toll-like receptors on dendritic cells to drive their maturation and antigen presentation, pushes T-cells toward a Th1 program, and activates an IDO-dependent regulatory arm — so it can restore suppressed immunity while damping over-reaction [5]. It is not a hormone that builds tissue and has no documented anabolic effect.
What is thymosin alpha 1 used for?
Clinically (where approved abroad) it is used mainly for chronic hepatitis B and as an immune adjuvant [4]. It has also been studied as an immunostimulatory adjuvant in cancer care — alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer [7] — and in sepsis and COVID-19, where results were mixed to null [3][8].
What is TA1 peptide?
TA1 (Tα1) is shorthand for Thymosin Alpha-1 — the same 28-amino-acid, acetylated thymic immune peptide whose sequence was determined in 1977 [1]. The abbreviation appears widely in research-use discussion; it refers to the immunomodulatory peptide, not to any tissue-repair or performance compound.
Is TB-500 the same as thymosin alpha 1?
No. TB-500 is thymosin beta-4, a 43-amino-acid actin-binding peptide studied for tissue repair; Thymosin Alpha-1 is a 28-amino-acid immune peptide first sequenced in 1977 [1]. They share only the historical name "thymosin" — different sequence, size, mechanism, and use. The full comparison is on the vs-thymosin-beta-4 page.
How long should you take thymosin alpha 1?
Study durations vary by setting: the chronic-hepatitis regimen runs as twice-weekly subcutaneous dosing over months, while sepsis trial protocols used roughly five to seven days [2][3]. A comprehensive review documents single doses across 0.8–6.4 mg and multiple-dose courses of 1.6–16 mg over five to seven days [4]. These are study protocols, not a recommended course for anyone.
How long does it take for thymosin alpha 1 to work?
There is no clean answer from the literature, because outcomes were measured by indication, not by onset of a felt effect. Pharmacologically it clears fast — a ~2-hour half-life, with blood levels back toward baseline within about 24 hours — which is why regimens repeat dosing [4]. As an immune modulator, its effects are biochemical and would not be something a person feels on a timeline.
What is the dosing protocol for thymosin alpha 1?
Reported protocols (not recommendations): 1.6 mg subcutaneously twice weekly in chronic hepatitis; 1.6 mg every 12 hours for five to seven days in sepsis trials [2][3]; 1.6 mg daily in COVID-19 cohorts [6]. A review summarizes single doses of 0.8–6.4 mg and courses of 1.6–16 mg over five to seven days [4]. This site reports what was studied; it does not prescribe.
How does thymosin alpha 1 make you feel?
Most people report feeling nothing noticeable — expected for an immune modulator that acts biochemically rather than producing a sensation. Anecdotally, some describe a vague sense of resilience or steadier energy during recovery, and a minority report a brief flu-like or achy day; these are unverified community impressions, not measured effects [4]. No dosing or experiential guidance is offered here.
How much thymosin alpha 1 should I take?
This site does not provide a dose. For context only, the literature reports single subcutaneous doses studied across 0.8–6.4 mg and a long-standing approved-abroad regimen of 1.6 mg twice weekly [4]. Those are study and label figures from clinical settings; they are not a recommendation, and decisions about any unapproved peptide belong with a qualified clinician.
When is the best time to take thymosin alpha 1?
The literature does not establish a "best time" — trial protocols specified frequency (for example, twice weekly, or every 12 hours in sepsis studies) rather than time of day [2][3]. Given the short ~2-hour half-life, regimens are built around dosing intervals, not clock timing [4]. This is descriptive of studied schedules, not advice.
Is thymosin alpha 1 safe to take?
In studied settings it is generally well tolerated: surveillance across more than 600,000 patients found mild injection-site reactions as the main adverse event and no organ toxicity at studied doses [15]. The real safety caveats are context — autoimmune disease, transplant, pregnancy [4][14] — and unregulated research-grade product quality [4]. "Well tolerated in trials" is not the same as "safe for unsupervised use."
Does thymosin alpha 1 help cancer?
The evidence is mixed. It has been reappraised as an immunostimulatory adjuvant alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer [7], but a Cochrane review of thymic peptides found no overall-survival benefit, with a non-significant pooled risk ratio of 1.21 for Thymosin Alpha-1 specifically [10]. Mechanistic promise as a combination agent; survival benefit remains unproven.